Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development

Author(s): Bin Chen, Jennifer Q. Dong, Wei-Jian Pan, Ana Ruiz

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 7 , 2012

Become EABM
Become Reviewer
Call for Editor


Pharmacokinetic/pharmacodynamic (PK/PD) modeling & simulation (M&S) provides quantitative assessment of dose/exposure-response relationships with extensive applications at the late stage drug development as well as during regulatory decision making. However, at preclinical and early phase clinical drug development, the importance of PK/PD M&S has not been as widely recognized. We reviewed selected PK/PD M&S literatures in order to convey importance of M&S in these early development phases. We focused on the application of M&S to select and optimize lead candidates, the use of preclinical PK/PD data to project the range of clinical doses, and the development of comprehensive dose/exposure-response models that can be used to forecast the probability of achieving a target response based on Phase 1 safety, PK and biomarker information. We also reviewed several other M&S approaches that are often used in early drug development such as physiologically-based pharmacokinetic (PBPK) modeling, meta-analysis, PK-pharmacogenomics modeling, and etc. Our aims were to provide expert opinions on the practical utility of PK/PD model-based approaches that have positive impact on early decision-making with the goal of improving the success rate of early to late stage drug development.

Keywords: Biopharmaceutical, drug discovery, early drug development, modeling & simulation, pharmacokinetics/ pharmacodynamics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 05 May, 2012
Page: [1360 - 1375]
Pages: 16
DOI: 10.2174/138920112800624436
Price: $65

Article Metrics

PDF: 66